Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Hypersensitivity Reactions to Native E. coli L-Asparaginase in Children with Acute Lymphoblastic Leukemia May Vary By Treatment Schedule and Type of Glucocorticoid in Induction: Results of Trial ALL-BFM 2000

Blood (2022) 140 (Supplement 1): 11676–11678.

https://doi.org/10.1182/blood-2022-163142

Published: 2022

Journal Articles

Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol

Blood (2022) 140 (Supplement 1): 109–111.

https://doi.org/10.1182/blood-2022-166583

Published: 2022

Journal Articles

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Carmelo Rizzari, Anja Moericke, MD, Valentino Conter, MD, Maria Grazia Valsecchi, PhD, Martin Zimmermann, PhD, Daniela Silvestri, Georg Mann, MD, Felix Niggli, MD, Luciano Dalla-Pozza, MBBS FRACP, Jan Stary, Prof., MD PhD, Sarah Elitzur, MD, Gunnar Cario, MD, Franco Locatelli, MD, Joachim Boos, MD, Massimo Zucchetti, PharmD, Andrea Biondi, MD, Martin Schrappe, MD PhD

Blood (2019) 134 (Supplement_1): 2589.

https://doi.org/10.1182/blood-2019-123448

Published: 2019

Journal Articles

Toxicity of Very Prolonged Pegasparaginase and Erwinia Asparaginase Courses in Relation to Asparaginase Activity Levels with a Special Focus on Dyslipidemia

Wing H. Tong, MD PhD, Rob Pieters, Hester A. de Groot-Kruseman, PhD, Wim C.J. Hop, PhD, Joachim Boos, MD PhD, Wim J Tissing, MD PhD, Inge M. van der Sluis, MD PhD

Blood (2014) 124 (21): 2256.

https://doi.org/10.1182/blood.V124.21.2256.2256

Published: 2014

Journal Articles

A germ line mutation in cathepsin B points toward a role in asparaginase pharmacokinetics

Laurens T. van der Meer, Esmé Waanders, Marloes Levers, Hanka Venselaar, Debbie Roeleveld, Joachim Boos, Claudia Lanvers, Roger J. Brüggemann, Roland P. Kuiper, Peter M. Hoogerbrugge, Frank N. van Leeuwen, D. Maroeska te Loo

Blood (2014) 124 (19): 3027–3029.

https://doi.org/10.1182/blood-2014-06-582627

Published: 2014

Includes: Supplemental data

Journal Articles

A Prospective Study On Drug Monitoring Of Pegasparaginase and Erwinia Asparaginase and Asparaginase Antibodies In Pediatric Acute Lymphoblastic Leukemia

Wing H. Tong, MD, Rob Pieters, Gertjan Kaspers, MD, PhD, Maroeska D.W.M. te Loo, MD, PhD, Marc Bierings, Cor van den Bos, MD, PhD, Wouter J.W. Kollen, MD, PhD, Wim C.J. Hop, PhD, Joachim Boos, MD, PhD, Mary V. Relling, PharmD, Hans Juergen Kuehnel, MD, Wim J Tissing, MD, PhD, Inge M. van der Sluis, MD, PhD

Blood (2013) 122 (21): 2634.

https://doi.org/10.1182/blood.V122.21.2634.2634

Published: 2013

Journal Articles

A Germline Mutation in Cathepsin B in a Child with ALL Points towards a Key Role for This Enzyme in L-Asparaginase Pharmacokinetics.

Laurens T. van der Meer, PhD, Esmé Waanders, PhD, Marloes Levers, BSc, Hanka Venselaar, MSc, Debbie Roeleveld, BSc, Joachim Boos, MD, PhD, Claudia Lanvers-Kaminsky, PhD, Roland P. Kuiper, PhD, Peter M. Hoogerbrugge, MD, PhD, Frank N. van Leeuwen, PhD, D. Maroeska W.M. te Loo, MD, PhD

Blood (2012) 120 (21): 2458.

https://doi.org/10.1182/blood.V120.21.2458.2458

Published: 2012

Journal Articles

Anti– Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials

Andrea Willer, Joachim Gerß, Thorsten König, Dieter Franke, Hans-Jürgen Kühnel, Günter Henze, Arendt von Stackelberg, Anja Möricke, Martin Schrappe, Joachim Boos, Claudia Lanvers-Kaminsky

Blood (2011) 118 (22): 5774–5782.

https://doi.org/10.1182/blood-2011-07-367904

Published: 2011

Includes: Supplemental data

Journal Articles

The Bone Marrow Niche of Patients with Acute Lymphoblastic Leukemia Produces No Increased Asparagine Levels In Vivo That May Lead to Clinical Asparaginase Resistance

Wing H. Tong, MD, Rob Pieters, MD, PhD, Wim C.J. Hop, PhD, Claudia Lanvers-Kaminsky, PhD, Joachim Boos, MD, PhD, Inge M. van der Sluis, MD, PhD

Blood (2011) 118 (21): 1505.

https://doi.org/10.1182/blood.V118.21.1505.1505

Published: 2011

Journal Articles

Population Pharmacokinetic of Native Escherichia Coli Asparaginase.

Stephan Borghorst, Rob Pieters, Hans Juergen Kuehnel, Joachim Boos, Georg Hempel

Blood (2009) 114 (22): 4803.

https://doi.org/10.1182/blood.V114.22.4803.4803

Published: 2009

Journal Articles

PEG-Asparaginase in Adult Acute Lymphoblastic Leukemia (ALL): Efficacy and Feasibility Analysis with Increasing Dose Levels

Nicola Goekbuget, MD, Anja Baumann, MD, Joachim Beck, MD, Joachim Boos, MD, PhD, Monika Brueggemann, MD, PhD, Helmut Diedrich, MD, Andreas Hüttmann, MD, Lothar Leimer, MD, Thomas Lipp, MD, Ralph Naumann, MD, PhD, Martin Mohren, MD, Albrecht Reichle, MD, PhD, Kerstin Schäfer-Eckart, MD, Marc Schmalzing, MD, Mathias Schmid, MD, PhD, Norbert Schmitz, MD, PhD, Theis Therwey, MD, Dieter Hoelzer, MD, PhD

Blood (2008) 112 (11): 302.

https://doi.org/10.1182/blood.V112.11.302.302

Published: 2008

Journal Articles

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95

Blood (2008) 111 (9): 4477–4489.

https://doi.org/10.1182/blood-2007-09-112920

Published: 2008

Includes: Supplemental data

Journal Articles

A Population Pharmacokinetic Model Describing the Activity-Time-Course of PEG-Asparaginase in Children.

Georg Hempel, Claudia Lanvers-Kaminsky, Hans-Joachim Mueller, Gudrun Wuerthwein, Joachim Boos

Blood (2004) 104 (11): 2746.

https://doi.org/10.1182/blood.V104.11.2746.2746

Published: 2004

Journal Articles

Pharmacology of PEG-asparaginase in childhood acute lymphoblastic leukemia (ALL)

Joao Paulo Vieira Pinheiro, Claudia Lanvers, Gudrun Würthwein, Joachim Boos

Blood (2002) 100 (5): 1923–1925.

https://doi.org/10.1182/blood-2002-04-1282

Published: 2002

NARROW

Hypersensitivity Reactions to Native E. coli L-Asparaginase in Children with Acute Lymphoblastic Leukemia May Vary By Treatment Schedule and Type of Glucocorticoid in Induction: Results of Trial ALL-BFM 2000

Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Toxicity of Very Prolonged Pegasparaginase and Erwinia Asparaginase Courses in Relation to Asparaginase Activity Levels with a Special Focus on Dyslipidemia

A germ line mutation in cathepsin B points toward a role in asparaginase pharmacokinetics

A Prospective Study On Drug Monitoring Of Pegasparaginase and Erwinia Asparaginase and Asparaginase Antibodies In Pediatric Acute Lymphoblastic Leukemia

A Germline Mutation in Cathepsin B in a Child with ALL Points towards a Key Role for This Enzyme in L-Asparaginase Pharmacokinetics.

Anti– Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials

The Bone Marrow Niche of Patients with Acute Lymphoblastic Leukemia Produces No Increased Asparagine Levels In Vivo That May Lead to Clinical Asparaginase Resistance

Population Pharmacokinetic of Native Escherichia Coli Asparaginase.

PEG-Asparaginase in Adult Acute Lymphoblastic Leukemia (ALL): Efficacy and Feasibility Analysis with Increasing Dose Levels

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95

A Population Pharmacokinetic Model Describing the Activity-Time-Course of PEG-Asparaginase in Children.

Pharmacology of PEG-asparaginase in childhood acute lymphoblastic leukemia (ALL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only